Report preliminary data for StealthX vaccine trial
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 13 Nov 2024
- Due
- 30 Jun 2025
- Checked
- 1 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Capricor expects that it will have preliminary data available in the second quarter of 2025”
What we found
Evidence strength A What the grades mean
The company reported that the Phase 1 trial for the StealthX vaccine did not initiate until August 2025, missing the deadline to report preliminary data by the second quarter of 2025.
-
A Capricor Therapeutics, Inc. 10-Q filed 2025-08-11
“Following the clearance of the Investigational New Drug (IND) application by the FDA, the Phase 1 study initiated in August 2025.” ✓ confirmed on the page
Market reaction: the shares moved -9.7% against the S&P 500 over the three sessions around the disclosure (8 Aug 2025 to 13 Aug 2025). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- preliminary data for StealthX vaccine trial
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: subject to FDA approval of the NIAID’s IND
- Depends on
- Regulatory, Partner
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Capricor Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-CAPR-002561 · Corrections policy